• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • China drug real-world study design and protocol framework guidelines is open for comments

China drug real-world study design and protocol framework guidelines is open for comments

China drug real-world study design
Friday, 22 July 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

China drug real-world study design and protocol framework guidelines is open for comments

China drug real-world study design and protocol framework guidelines (2022 Draft) has been released by the Center for Drug Evaluation (CDE) on July 7, 2022, for industry stakeholder comments. Feedback can be submitted until September 7, 2022 (see below for further information).

Highlights

The guideline applies to clinical evidence of drug evaluation obtained through real-world studies.

Main types of China drug real-world study design

  1. Observational study design: Although there are many types of observational studies, this guideline refers to cohort studies. Cohort studies can be divided into retrospective, prospective, and retrospective prospective cohort studies.
  2. Pragmatic Clinical Trial (PCT): The study refers to a clinical trial that is as close as possible to real-world clinical practice, and is something between randomized controlled clinical trial (RCT) and observational studies, which is interventional study.
  3. Single-arm study design: If the one-arm research is interventional, it is a one-arm test; If non-intrusive, it is a one-arm observational study. Whether interventional or non-interventional, one-arm study designs should generally have external controls in the form of historical or parallel controls based on natural history cohort data for disease or other external data, or target value controls.

Main framework of the real-world research protocol

The main framework of real-world research protocols of different design types are basically the same. The guideline suggests that the framework should cover the protocol summary, research background, research purpose, overall design, study population, treatment or intervention, study endpoints, baseline variables and important covariates, data governance / data management plan, bias consideration, statistical analysis plan, quality control, etc., however, special consideration for additional contents may be needed depending on each individual research project.

How to submit comments

The deadline for comments is September 7, 2022. Cisema customers may submit their feedback to their regulatory affairs project manager otherwise feedback can be sent to: zhaojun@cde.org.cn.

Further information

The guideline further describes in detail the key points for consideration of the above real-world designs, and the technical requirements for the feasibility of real-world research paths, representativeness of target population, mixed study designs, virtual control methods, estimated targets, etc. If you would like to learn more about the details, please contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

Simplifications of Clinical Studies
New CNAS Accreditation for Group Enterprise Internal Laboratories Explained
NMPA Approves Supplementary Testing Methods for Medical Dressing Patches

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.